Status:
COMPLETED
Helicobacter Pylori Eradication With a New Sequential Treatment
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Helicobacter Pylori Infection
Non Ulcer Dyspepsia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the era...
Detailed Description
One thousand and forty-nine dyspeptic patients were studied prospectively. H. pylori-infected patients were randomized to receive 10-day sequential therapy \[rabeprazole (20 mg twice daily) plus amoxi...
Eligibility Criteria
Inclusion
- Presence of active H. pylori infection
- Age \>18 years
Exclusion
- Allergy to drug administered
- Liver or kidney failure
- Pregnancy
- Previous treatment for H. pylori infection
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
End Date :
December 1 2001
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00132171
Start Date
January 1 2001
End Date
December 1 2001
Last Update
March 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology - Nuovo Regina Margherita Hospital
Rome, Italy, 00153